TrademarkIQ íconeTrademarkIQ
Voltar para busca
Dado oficial do USPTO

SAMIRNA

Sabia que essa marca já está registrada no Estados Unidos?

Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.

Active USPTO registrationTipo: VerbalEscritório: US

Snapshot rápido

SAMIRNA

ST13

US500000086287682

Classe

1, 5, 10, 42

Pedido

86287682

Registro

5052167

Diagnóstico de risco e oportunidade

Leitura executiva para decisão de naming, protocolo e monitoramento.

Atenção: há risco ativo

Situação USPTO

Active USPTO registration

Tipo de processo

Pedido e registro

Eventos registrados

44

Atualização mais recente

09/07/2026

Classificação

Registrada

Tipo de marca

Verbal

Classes Nice

1, 5, 10, 42

Data de depósito

21/05/2014

Data de registro

04/10/2016

Data de expiração

-

Ação recomendada

Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.

Próximo passo

Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.

Dados completos do processo

Campos estruturados da autoridade responsável e do histórico oficial.

Data da situação

05/10/2022

Última transação

09/07/2026

Escritório responsável

United States Patent and Trademark Office

Código da situação

704

Cadastro oficial

Principal Register

Fundamento do pedido

Intent to use, Foreign priority

Código do desenho

4

Tipo de titular

03

Localização do titular

Daejeon, KR

Examinador

KING, CHRISTINA B

Unidade examinadora

L90

Titulares e representantes

Titulares

B. C. (pessoa física)
B. C. (pessoa física)

Representantes

Jun-Hwa Jeong RABIN & BERDO, P.C.

Classificação técnica

Classes Nice

Classe 1Classe 5Classe 10Classe 42

Códigos Vienna

Sem códigos Vienna disponíveis.

Produtos e serviços

Classe 1

Diagnostic preparations for research use; Reagents for scientific research use; Chemicals for laboratory analyses, other than for medical use, namely, chemicals for use in biotechnological product development; Chemicals for pharmaceutical purposes, namely, for use in the manufacture of drugs and medicines; Chemicals for the manufacture of medical products in the nature of pharmaceutical preparations; Biochemicals, namely, biochemical reagents used for non-medical purposes; Chemical preparations for the manufacture of medical products

Classe 5

Pharmaceutical preparations for the treatment of cancer, tumor, respiratory disease, immunization disease, skin disease, viral disease, allergies; Biological preparations for the treatment of cancer, tumor, respiratory disease, immunization disease, skin disease, viral disease, allergies; Medicated vaccines and serums for treatment of cancer, tumor, respiratory disease, immunization disease, skin disease, viral disease, allergies; Capsules sold empty for pharmaceutical purposes for the treatment of cancer, tumor, respiratory disease, immunization disease, skin disease, viral disease, allergies; Microspheres containing pharmaceutical preparations, for treating cancer, tumor, respiratory disease, immunization disease, skin disease, viral disease, allergies; Preparations and substances for facilitating delivery of pharmaceutical preparations, namely, drug delivery agent in the form of nanoparticle for transferring siRNA in the cell; Carriers for drug delivery, namely, drug delivery agent in the form of nanoparticle for transferring siRNA in the cell; Peptides for drug delivery, namely, drug delivery agents consisting of peptides attached to drugs that facilitate delivery of pharmaceutical preparations; Pharmaceutical preparations applied pharmaceutical drug delivery system, namely, elixirs for the treatment of cancer, tumor, respiratory disease, immunization disease, skin disease, viral disease, allergies and a nanoparticle carrier for transferring siRNA in the cell or peptide; Chemical reagents for medical use; Pharmaceutical preparations for drug delivery into cells; Drug delivery formulations, namely, compositions consisting of nanoparticle for transferring siRNA in the cell or peptides; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals for medical purpose; Pharmaceutical preparations and substances for facilitating drug delivery in the form of nanoparticle for transferring siRNA in the cell or peptide for use in medical treatment via inhibition of gene expression; Pharmaceutical preparations containing RNA for use in medical treatment via inhibition of gene expression; Pharmaceutical preparations containing DNA for use in medical treatment via inhibition of gene expression

Classe 10

[ Drug delivery system; Implantable drug syringes for drug delivery devices; Implantable drug delivery pumps for drug delivery devices; Medical apparatus for introducing pharmaceutical preparations into the human body; Medical apparatus for facilitating the inhalation of pharmaceutical preparations; Injection device for pharmaceuticals; Microspheres, namely, unilaminar and bilaminar spherical particles comprising hydrophilic and hydrophobic polymers with diameters in the nanometer range used as a means for drug delivery for treating cancer, tumor, respiratory disease, immunization disease, skin disease, viral disease, allergies ]

Classe 42

Pharmaceutical products research; Pharmaceutical products development; Research for medical products; Crude medicines research; Research and development of biotechnology for others; Quality control, namely, quality control of target gene expression activity with siRNA; Biotechnology research

Publicações

Histórico de despachos e eventos da marca no USPTO.

44 publicações encontradas

E89R

TEAS SECTION 8 & 9 RECEIVED

07/07/2026

REM2

COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED

04/10/2025

NAS8

NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED

05/10/2022

8.PR

REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED

05/10/2022

APRE

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

04/10/2022

ES8R

TEAS SECTION 8 RECEIVED

26/04/2022

REM1

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED

04/10/2021

R.PR

REGISTERED-PRINCIPAL REGISTER

04/10/2016

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

19/07/2016

PUBO

PUBLISHED FOR OPPOSITION

19/07/2016

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

29/06/2016

PREV

LAW OFFICE PUBLICATION REVIEW COMPLETED

15/06/2016

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

08/06/2016

XAEC

EXAMINER'S AMENDMENT ENTERED

08/06/2016

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

08/06/2016

GNEA

EXAMINERS AMENDMENT E-MAILED

08/06/2016

CNEA

EXAMINERS AMENDMENT -WRITTEN

08/06/2016

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

21/05/2016

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

20/05/2016

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

20/05/2016

GPRN

NOTIFICATION OF PRIORITY ACTION E-MAILED

23/11/2015

GPRA

PRIORITY ACTION E-MAILED

23/11/2015

CPRA

PRIORITY ACTION WRITTEN

23/11/2015

DMCC

DATA MODIFICATION COMPLETED

16/11/2015

ALIE

ASSIGNED TO LIE

16/11/2015

DOCK

ASSIGNED TO EXAMINER

09/11/2015

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

23/10/2015

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

23/10/2015

ERSI

TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED

23/10/2015

GNS2

NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED

21/08/2015

GNSI

INQUIRY TO SUSPENSION E-MAILED

21/08/2015

CNSI

SUSPENSION INQUIRY WRITTEN

21/08/2015

GNS3

NOTIFICATION OF LETTER OF SUSPENSION E-MAILED

06/02/2015

GNSL

LETTER OF SUSPENSION E-MAILED

06/02/2015

CNSL

SUSPENSION LETTER WRITTEN

06/02/2015

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

05/02/2015

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

04/02/2015

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

04/02/2015

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

04/08/2014

GNRT

NON-FINAL ACTION E-MAILED

04/08/2014

CNRT

NON-FINAL ACTION WRITTEN

04/08/2014

DOCK

ASSIGNED TO EXAMINER

04/08/2014

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

04/06/2014

NWAP

NEW APPLICATION ENTERED

24/05/2014

Proteção contínua da sua marca

Seja avisado a cada novo depósito que ameace SAMIRNA ou a sua marca.

Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.